Detailed Information
Cited 31 time in 
Cited 33 time in 
Cited 33 time in
Metadata Downloads
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
- Authors
- Witzig, TE[Witzig, T. E.]; Tobinai, K[Tobinai, K.]; Rigacci, L[Rigacci, L.]; Ikeda, T[Ikeda, T.]; Vanazzi, A[Vanazzi, A.]; Hino, M[Hino, M.]; Shi, Y[Shi, Y.]; Mayer, J[Mayer, J.]; Costa, LJ[Costa, L. J.]; Silva, CDB[Bermudez Silva, C. D.]; Zhu, J[Zhu, J.]; Belada, D[Belada, D.]; Bouabdallah, K[Bouabdallah, K.]; Kattan, JG[Kattan, J. G.]; Kuruvilla, J[Kuruvilla, J.]; Kim, WS[Kim, W. S.]; Larouche, JF[Larouche, J-F]; Ogura, M[Ogura, M.]; Ozcan, M[Ozcan, M.]; Fayad, L[Fayad, L.]; Wu, C[Wu, C.]; Fan, J[Fan, J.]; Louveau, AL[Louveau, A-L]; Voi, M[Voi, M.]; Cavalli, F[Cavalli, F.]
- Issue Date
- Mar-2018
- Publisher
- OXFORD UNIV PRESS
- Keywords
- Adjuvant therapy; everolimus; large cell lymphoma
- Citation
- ANNALS OF ONCOLOGY, v.29, no.3, pp.707 - 714
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 29
- Number
- 3
- Start Page
- 707
- End Page
- 714
- ISSN
- 0923-7534
- Abstract
- Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) a parts per thousand 3 are at higher risk for relapse after a complete response (CR) to first-line rituximab-based chemotherapy (R-chemo). Everolimus has single-agent activity in lymphoma. PILLAR-2 aimed to improve disease-free survival (DFS) with 1 year of adjuvant everolimus.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.